FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569876810> ?p ?o ?g. }

• W2569876810 abstract "Abstract Introduction. Supportive care has traditionally been the primary treatment for patients with MDS. The approval of hypomethylating agents provides therapeutic options for these patients. However more knowledge about the clinical benefits and associated economic implications in the community setting are required to understand how to best incorporate them into clinical guidelines and protocols. This pharmacoeconomic evaluation was conducted to address critical inputs for this medical decision making process. Method. This evaluation is based on the retrospective analysis of medical and billing records for patients receiving treatment from January, 2006 to December, 2007, in the community setting. Only patients that received initial non-supportive care treatment with a hypomethylating agent decitabine (Dacogen (DAC)) or azacitidine (Vidaza (VID)) were included for this analysis. Due to the progressive nature of this disease, a longitudinal evaluation of the lines of therapy was conducted. Total costs per cycle were defined as the total costs associated with the utilization of hypomethylating agents, other downstream MDS treatments (eg lenalidomide), antiemetics, erythropoietins, WBC growth factors, and transfusions. The costs of antibiotics and antifungals were not included as the established treatment regimens were the same between the specified intervention protocols. The clinical response (CRp) based on available peripheral blood measures with a response being defined as Hgb ≥ 11 g/dL with no transfusions or erythropoietin use, ANC ≥ 1000/μL without the use of WBC growth factors, platelets ≥ 100,000/μL with no thrombopoietic agent, and no blasts for at least 4 weeks. The time to response and transfusion independence were determined by the individual cycles within the lines of therapy. The total and individual cost components were evaluated for each line of therapy based on the sequence of treatment received by cycles. The distribution of clinical response, transfusion independence, and other patient characteristics were analyzed using Chi-square tests and time to response and transfusion was compared using Kaplan-Meier methods. An incremental cost-effective ratio defined as the difference in cost between DAC and VID divided by the difference in CRp or time to response was calculated. Results. A total of 70 patients received initial treatment with either DAC (40) or VID (30). Patients receiving DAC were treated a median of 2.5 cycles of initial treatment while those on VID were treated for a median of 3.5 cycles. No differences in baseline IPSS score were seen. Approximately 43% of those treated with Dacogen had a CRp compared to 13% of patients on VID (p=0.0095). The mean time to response was 105.8 and 130.9 days for DAC and VID, respectively (p=0.0018). The total costs from initial treatment to response were $16,679.19 and $13,954.33 for DAC and VID, respectively (p=0.47). Those with a CRp on DAC had a mean total cost of $34,435.62 compared to $36,852.57 with a CRp on VID with the number of cycles ranging from 2 to 13 for DAC and 8 to 9 for VID. However the mean total cost for those without a response to VID was $23,434.22 compared to $19,111.60 for those not responding to DAC. More patients receiving VID received other MDS agents after initial treatment than those receiving DAC, resulting in increased overall expenses over the remaining treatment period for these patients. The resulting incremental CE ratio based on CRp was $1336.60 per additional successfully treated patient while the incremental CE ratio using time to response was $108.56/day. Discussion. Hypomethylating agents provide clinicians with necessary alternatives to traditional supportive care in the treatment of patients with MDS. Due to faster time to clinical response, Dacogen appears to have both a short- and long-term pharmacoeconomic advantage over Vidaza. Extended observation of patients and length of treatment is needed to understand the long-term ramifications for incorporation into clinical guidelines and protocols." @default.
• W2569876810 created "2017-01-13" @default.
• W2569876810 creator A5029230498 @default.
• W2569876810 creator A5044542360 @default.
• W2569876810 creator A5050866878 @default.
• W2569876810 creator A5087541775 @default.
• W2569876810 creator A5091852151 @default.
• W2569876810 creator A5078050052 @default.
• W2569876810 date "2008-11-16" @default.
• W2569876810 modified "2023-09-27" @default.
• W2569876810 title "Pharmacoeconomic Evaluation of Hypomethylating Agents Used for the Treatment of MDS" @default.
• W2569876810 doi "https://doi.org/10.1182/blood.v112.11.2380.2380" @default.
• W2569876810 hasPublicationYear "2008" @default.
• W2569876810 type Work @default.
• W2569876810 sameAs 2569876810 @default.
• W2569876810 citedByCount "1" @default.
• W2569876810 crossrefType "journal-article" @default.
• W2569876810 hasAuthorship W2569876810A5029230498 @default.
• W2569876810 hasAuthorship W2569876810A5044542360 @default.
• W2569876810 hasAuthorship W2569876810A5050866878 @default.
• W2569876810 hasAuthorship W2569876810A5078050052 @default.
• W2569876810 hasAuthorship W2569876810A5087541775 @default.
• W2569876810 hasAuthorship W2569876810A5091852151 @default.
• W2569876810 hasConcept C104317684 @default.
• W2569876810 hasConcept C126322002 @default.
• W2569876810 hasConcept C150194340 @default.
• W2569876810 hasConcept C177713679 @default.
• W2569876810 hasConcept C185592680 @default.
• W2569876810 hasConcept C190727270 @default.
• W2569876810 hasConcept C2776012956 @default.
• W2569876810 hasConcept C2776063141 @default.
• W2569876810 hasConcept C2776239401 @default.
• W2569876810 hasConcept C2776364478 @default.
• W2569876810 hasConcept C2780235182 @default.
• W2569876810 hasConcept C55493867 @default.
• W2569876810 hasConcept C71924100 @default.
• W2569876810 hasConceptScore W2569876810C104317684 @default.
• W2569876810 hasConceptScore W2569876810C126322002 @default.
• W2569876810 hasConceptScore W2569876810C150194340 @default.
• W2569876810 hasConceptScore W2569876810C177713679 @default.
• W2569876810 hasConceptScore W2569876810C185592680 @default.
• W2569876810 hasConceptScore W2569876810C190727270 @default.
• W2569876810 hasConceptScore W2569876810C2776012956 @default.
• W2569876810 hasConceptScore W2569876810C2776063141 @default.
• W2569876810 hasConceptScore W2569876810C2776239401 @default.
• W2569876810 hasConceptScore W2569876810C2776364478 @default.
• W2569876810 hasConceptScore W2569876810C2780235182 @default.
• W2569876810 hasConceptScore W2569876810C55493867 @default.
• W2569876810 hasConceptScore W2569876810C71924100 @default.
• W2569876810 hasLocation W25698768101 @default.
• W2569876810 hasOpenAccess W2569876810 @default.
• W2569876810 hasPrimaryLocation W25698768101 @default.
• W2569876810 hasRelatedWork W148448903 @default.
• W2569876810 hasRelatedWork W2018503916 @default.
• W2569876810 hasRelatedWork W2121888504 @default.
• W2569876810 hasRelatedWork W2139589768 @default.
• W2569876810 hasRelatedWork W2332888891 @default.
• W2569876810 hasRelatedWork W2410407484 @default.
• W2569876810 hasRelatedWork W2522004864 @default.
• W2569876810 hasRelatedWork W2530643391 @default.
• W2569876810 hasRelatedWork W2533687809 @default.
• W2569876810 hasRelatedWork W2559347286 @default.
• W2569876810 hasRelatedWork W2561539533 @default.
• W2569876810 hasRelatedWork W2561604853 @default.
• W2569876810 hasRelatedWork W2565383729 @default.
• W2569876810 hasRelatedWork W2566813663 @default.
• W2569876810 hasRelatedWork W2588934703 @default.
• W2569876810 hasRelatedWork W2594668246 @default.
• W2569876810 hasRelatedWork W2779973765 @default.
• W2569876810 hasRelatedWork W2941099750 @default.
• W2569876810 hasRelatedWork W2972698438 @default.
• W2569876810 hasRelatedWork W3006645018 @default.
• W2569876810 isParatext "false" @default.
• W2569876810 isRetracted "false" @default.
• W2569876810 magId "2569876810" @default.
• W2569876810 workType "article" @default.